NTRK1 and cancer: Targeting tyrosine kinases (TKs), including receptor tyrosine kinases (RTKs), has been particularly effective in pediatric cancers in the context of bona fide activating events, such as the BCR::ABL1 fusion gene, and as such, identifying alterations in TK genes remains a high-priority in precision medicine3.